

**Registry of Patients with Pulmonary
Hypertension Presented to
Ain-Shams University Hospitals**

Thesis

*Submitted for Partial Fulfillment of Doctorate
Degree in Cardiology*

By

Abdelrahman Elsayed Attia Abdelwahed
Ain Shams University

Under supervision of

Prof. Maiy Hamdy Elsayed

*Professor of Cardiology
Faculty of Medicine - Ain Shams University*

Dr. Hebatallah Mohamed Attia

*Assistant Professor of Cardiology
Faculty of Medicine - Ain Shams University*

Dr. Dina Adel Ezzeldin

*Lecturer of Cardiology
Faculty of Medicine - Ain Shams University*

Faculty of Medicine - Ain Shams University

2019

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سببناك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**, the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Maiy Hamdy Elsayed**, Professor of Cardiology, Faculty of Medicine-Ain Shams University for her keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Dr. Hebatallah Mohamed Attia**, Assistant Professor of Cardiology, Faculty of Medicine, Ain Shams University, for her kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I am deeply thankful to **Dr. Dina Adel Ezzeldin**, Lecturer of Cardiology, Faculty of Medicine, Ain Shams University, for her great help, active participation and guidance.*

I would like to express my hearty thanks to all my family for their support till this work was completed.

Last but not least my sincere thanks and appreciation to all patients participated in this study.

Abdelrahman Elsayed Attia Abdelwahed

List of Contents

Title	Page No.
List of Tables	i
List of Figures	iii
List of Abbreviations	v
Introduction	1
Aim of the Work.....	2
Review of Literature	
Pulmonary Hypertension	3
Risk Assessment of Pulmonary Hypertension	11
Specific Entities of Pulmonary Hypertension.....	23
Patients and Methods	26
Results	48
Discussion	87
Summary	116
Limitations & Recommendations	118
Recommendations	119
References	121
Arabic Summary	

List of Tables

Table No.	Title	Page No.
Table (1):	Risk assessment	13
Table (2):	Basic characteristics:.....	50
Table (3):	Symptoms and previous history:	51
Table (4):	The etiology.....	52
Table (5):	Echocardiography data	53
Table (6):	Echocardiography, continued	54
Table (7):	Pre-existing medical treatment	55
Table (8):	Catheterization data.....	57
Table (9):	Intervention	57
Table (10):	Complications after cath.....	58
Table (11):	Further plan	58
Table (12):	Follow up	59
Table (13):	Basic characteristics	60
Table (14):	Symptoms and previous history.....	61
Table (15):	Etiology	62
Table (16):	Echocardiography data	63
Table (17):	Echocardiography data, continued	64
Table (18):	Pre-existing medical treatment	65
Table (19):	Catheterization data:	67
Table (20):	Intervention	67
Table (21):	Complications after cath.....	68
Table (22):	Further plan	68
Table (23):	Follow up	69
Table (24):	6MWT.....	70
Table (25):	Complications.....	70
Table (26):	DOWN syndrome.....	71
Table (27):	Catheterization data in DOWN syndrome	72
Table (28):	Eisenmenger syndrome.....	73
Table (29):	Relation between MPAP and the etiology of PHTN	74
Table (30):	Relation between PVR and the etiology of PHTN	74

List of Tables (cont...)

Table No.	Title	Page No.
Table (31):	Relation between 6MWT before and after ASD closure	75
Table (32):	Relation between MPAP, syncope and L.L swelling.....	75
Table (33):	Relation between MPAP, and RV functions by TAPSE and FAC	76
Table (34):	Relation between syncope, MPAP and 6MWT.....	76
Table (35):	Relation between L.L swelling, MPAP and 6MWT.....	77
Table (36):	Relation between RV functions by TAPSE and MPAP, 6MWT	77
Table (37):	Relation between RV functions by FAC and MPAP, 6MWT	78
Table (38):	Relation between complications, MPAP and 6MWT.....	78
Table (39):	Relation between MPA diameter and MPAP.....	79
Table (40):	Treatment in TOPP registry	106

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Diagram and corresponding echocardiographic apical 4- chamber image showing the right ventricular basal and mid cavity RV minor dimensions and the RV longitudinal dimension.....	17
Figure (2):	Measurement of tricuspid annular plane systolic excursion	19
Figure (3):	RV FAC in RV-focused apical four-chamber view	20
Figure (4):	31
Figure (5):	Tricuspid annular plane systolic excursion. Patient number 12.....	32
Figure (6):	FAC of the RV from RV-Focused 4 chamber view. Patient number 29.....	33
Figure (7):	RV dimensions in RV-focused view. Patient number 3.....	34
Figure (8):	Maximum TR jet velocity for estimation of the RVSP. Patient number 6.....	35
Figure (9):	The enclosed Corridor used in the 6MWT.....	38
Figure (10):	West nomogram (for estimation of BSA).....	42
Figure (11):	Basic characteristics.....	49
Figure (12):	The etiology	52
Figure (13):	Medical treatment.....	55
Figure (14):	The etiology	62
Figure (15):	Medical treatment:	65
Figure (16):	Patient no.15: ASD device closing ASD under TEE and fluoroscopic guidance.....	80
Figure (17):	Patient no.125: VSD device closing large PDA.....	80

List of Figures

Fig. No.	Title	Page No.
Figure (18):	Patient no.58: TEE used for assessment of ASD.....	81
Figure (19):	Patient no.58: 3D TEE used for better assessment of ASD	81
Figure (20):	Patient no.45: A modified short axis parasternal view showing a large sized restrictive PDA measuring 5 mm with left to right shunt with color turbulence across.	82
Figure (21):	Patient no 130: showing a fluoroscopy image of 35 years old patient during ASD device closure	82
Figure (22):	Patient no.38: dilated LV dimensions with impaired functions due to severe coarctation	83
Figure (23):	Patient no.127: dilated non collapsible IVC, estimated RAP of 15mmHg.....	83
Figure (24):	Patient no.143: D shaped LV due to the dilated RV	84
Figure (25):	Patient no.115: hemodynamic study in patient with complex congenital heart disease	84
Figure (26):	Patient no.56: patient with loose PA band.....	85
Figure (27):	Patient no.56: patient with loose PA band.....	85
Figure (28):	Patient no.2: patient underwent surgical VSD closure	86
Figure (29):	Patient no.24: hemodynamic study in patient with mal-posed great vessels.	86
Figure (30):	Treatment in REVEAL registry.....	105

List of Abbreviations

<i>Abb.</i>	<i>Full term</i>
<i>6MWD</i>	<i>6-minute walking distance</i>
<i>ASD</i>	<i>Atrial septal defect</i>
<i>BNP</i>	<i>Brain natriuretic peptide</i>
<i>CBC</i>	<i>Complete blood count</i>
<i>CCBs</i>	<i>Calcium channel blockers</i>
<i>CHD</i>	<i>Congenital heart disease</i>
<i>CI</i>	<i>Cardiac index</i>
<i>CMR</i>	<i>Cardiac magnetic resonance</i>
<i>CT</i>	<i>Computed tomography</i>
<i>DVT</i>	<i>Deep vein thrombosis</i>
<i>ECG</i>	<i>Echocardiography</i>
<i>EMA</i>	<i>European Medicines Agency</i>
<i>ERAs</i>	<i>Endothelin receptor antagonists</i>
<i>ES</i>	<i>Eisenmenger's syndrome</i>
<i>ET</i>	<i>Endothelin</i>
<i>FAC</i>	<i>Fractional area change</i>
<i>FDA</i>	<i>Food and Drug Administration</i>
<i>GE</i>	<i>General Electric</i>
<i>IPAH</i>	<i>Idiopathic pulmonary arterial hypertension</i>
<i>IUGR</i>	<i>Intrauterine growth retardation</i>
<i>MPAP</i>	<i>Mean PA Pressure</i>
<i>NT-proBNP</i>	<i>N-terminal pro-brain natriuretic peptide</i>
<i>PADP</i>	<i>PA Diastolic Pressure</i>

List of Abbreviations (cont...)

Abb.	Full term
<i>PAH</i>	<i>Pulmonary arterial hypertension</i>
<i>PAPUCO</i>	<i>Pan African Pulmonary hypertension Cohort</i>
<i>PDA</i>	<i>Patent ductus arteriosus</i>
<i>PDE-5i</i>	<i>Phosphodiesterase type 5 inhibitors</i>
<i>PH</i>	<i>Pulmonary hypertension</i>
<i>pred.</i>	<i>Predicted</i>
<i>PROs</i>	<i>Patient-reported outcomes</i>
<i>PVOD</i>	<i>Pulmonary vascular occlusive disease</i>
<i>PVR</i>	<i>Pulmonary vascular resistance</i>
<i>QoL</i>	<i>Quality-of-life</i>
<i>RA</i>	<i>Right atrium</i>
<i>RAP</i>	<i>Right atrial pressure</i>
<i>RHD</i>	<i>Rheumatic heart disease</i>
<i>RV</i>	<i>Right ventricle</i>
<i>RVH</i>	<i>RV hypertrophy</i>
<i>RVSP</i>	<i>Right ventricle systolic pressure</i>
<i>SvO2</i>	<i>Mixed venous oxygen saturation</i>
<i>TAPSE</i>	<i>Tricuspid annular plane systolic excursion</i>
<i>VE/VCO2</i>	<i>Ventilator equivalents for carbon dioxide</i>
<i>VO2</i>	<i>Oxygen consumption</i>
<i>VSD</i>	<i>Ventricular septal defect</i>
<i>WHO</i>	<i>World Health Organization</i>

INTRODUCTION

Pulmonary hypertension is a Patho-physiological disorder that involves multiple clinical conditions and can complicate many cardiovascular and respiratory diseases (*Sliwa et al., 2012*).

Registries of patients with pulmonary arterial hypertension (PAH) have been instrumental in characterizing the presentation and history of the disease providing a basis for prognostication. Since initial accumulation of data conducted in the 1980s, subsequent registry databases have yielded information about the demographic factors, treatment, and survival and have permitted comparisons between populations in different eras and environments. Inclusion of patients with all subtypes of PAH has also allowed comparisons of these subpopulations (*Mocumbi et al., 2011; Thienemann et al., 2016*).

The epidemiology of pulmonary hypertension and its burden has not been studied yet in Egypt, in 2016, chest hospital in Abbasiya tried to retrospectively study 52 patients with pulmonary hypertension with trial to increase awareness about pulmonary hypertension among its physicians (*Farrag et al., 2016*).

Another trial in 2016 studied pulmonary hypertension in adult Egyptian patients with b-thalassemia major and its correlation with natural anticoagulant levels (*Elbedewy et al., 2015*).

AIM OF THE WORK

To establish a registry for patients with pulmonary hypertension including their clinical data, echocardiographic evaluation, any intervention and the clinical outcome for patients presented to congenital and structural heart disease unit at Ain shams university hospitals.

*Chapter 1***PULMONARY HYPERTENSION**

Definition: Pulmonary hypertension is a complex group of disorders which result from different pathophysiologic mechanisms but are all defined by a mean pulmonary arterial pressure of 25 mm Hg or more measured by RHC (*Galie et al., 2016*).

PAH-CHD represents a preventable form of PAH in the recent decades, advances in diagnostic procedures and cardiac surgery have resulted in the prevention of PAH in most children with CHD and systemic-pulmonary shunts in Western countries; this is, unfortunately, not yet the case in developing countries (*Chessa et al., 2017*).

The clinical classification of pulmonary hypertension according to international pulmonary hypertension guidelines (*Simonneau et al., 2013*):

- 1- Pulmonary arterial hypertension.
- 2- Pulmonary hypertension due to left heart disease.
- 3- Pulmonary hypertension due to lung diseases and/or hypoxia.
- 4- Chronic thromboembolic pulmonary hypertension and other pulmonary artery obstructions.

- 5- Pulmonary hypertension due to unclear and/or multifactorial mechanism.

Pathophysiology:

All congenital heart defects, in which a large intra or extra cardiac communication allows unrestricted pressure and volume overload of the pulmonary circulation, may lead to the development of pulmonary arterial hypertension (PAH), unless repair occurs in early childhood (*Dimopoulos et al., 2014*).

Pulmonary arterial hypertension (PAH, group 1) is a clinical condition characterized by the presence of pre-capillary PH and pulmonary vascular resistance >3 Wood units, in the absence of other causes of pre-capillary PH (*Galie et al., 2016*).

Clinical classification of pulmonary arterial hypertension associated with congenital heart disease (*Rubin et al., 2013; D'alto et al., 2015; Galie et al., 2016*):

1. Eisenmenger's syndrome (ES):

Includes all large intra- and extra-cardiac defects which begin as systemic-to-pulmonary shunts and progress with time to severe elevation of PVR and to reversal or bidirectional shunting; cyanosis, secondary erythrocytosis, and multiple organ involvement are usually present.

2. PAH associated with prevalent systemic-to-pulmonary shunts:

- Correctable.
- Non-correctable.

Includes moderate to large defects; PVR is mildly to moderately increased, systemic-to-pulmonary shunting is still prevalent, whereas cyanosis at rest is not a feature.

3. PAH with small/incidental defects:

Marked elevation in PVR in the presence of small cardiac defects (usually ventricular septal defects <1 cm and atrial septal defects < 2 cm of effective diameter assessed by echo), which themselves do not account for the development of elevated PVR; the clinical picture is very similar to idiopathic PAH. Closing the defects is contra-indicated.

4. PAH after defect correction:

Congenital heart disease is repaired, but PAH either persists immediately after correction or recurs/develops months or years after correction in the absence of significant postoperative hemodynamic lesions.

Congenital heart disease accounts for nearly one-third of all major congenital anomalies, nearly 1 in 100 children are born with congenital heart disease (6–10/1000 live births),